Novel and Emerging Drugs for Acute Lymphoblastic Leukemia

Author(s): E. Lech-Maranda , W. Mlynarski .

Journal Name: Current Cancer Drug Targets

Volume 12 , Issue 5 , 2012

Become EABM
Become Reviewer


Over the past several decades the important progress has been made in the management of acute lymphoblastic leukemia (ALL), especially among children. However, in adult patients reported cure rates seldom exceeded 40%, despite the use of hematopoietic stem-cell transplantation in many cases. Conventional chemotherapy is toxic and ineffective. Therefore, new treatment options and risk-adapted therapies are needed to improve the outcome of ALL patients. This review is focused on new systemic treatment modalities, such as nucleoside analogues, purine synthetase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors and other agents targeting molecular pathways that are aimed to benefit patients and improve the outcome of their treatment.

Keywords: Acute lymphoblastic leukemia, blinatumomab, DOT1L inhibitors, JAK/STAT inhibitors, monoclonal antibodies, mTOR inhibitors, NOTCH inhibitors, nucleoside analogues, tyrosine kinase inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [505 - 521]
Pages: 17
DOI: 10.2174/156800912800673275
Price: $58

Article Metrics

PDF: 8